What is CRISPR Therapeutics AG 5-Year Yield-on-Cost %?
CRISPR Therapeutics AG's yield on cost for the quarter that ended in Dec. 2023 was 0.00.
The historical rank and industry rank for CRISPR Therapeutics AG's 5-Year Yield-on-Cost % or its related term are showing as below:
CRSP's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.92 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Competitive Comparison of CRISPR Therapeutics AG's 5-Year Yield-on-Cost %
For the Biotechnology subindustry, CRISPR Therapeutics AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's 5-Year Yield-on-Cost % falls into.
CRISPR Therapeutics AG 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
CRISPR Therapeutics AG (NAS:CRSP) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
CRISPR Therapeutics AG 5-Year Yield-on-Cost % Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your